

Editorial

Charting the Future of Cancer and Organ Failure Care: A New Forum for Oncology, Nuclear Medicine and Transplantology

Zhandos Burkitbayev¹

¹Chairman of the Board, National Research Oncology Center, Astana, Kazakhstan

Received: Sep 21, 2025

Accepted: Sep 24, 2025

Corresponding author's email:
Zhan11@mail.ru



This work is licensed under a
Creative Commons Attribution 4.0
International License

Abstract:

This inaugural editorial introduces the new journal, "Oncology, Nuclear Medicine and Transplantology," launched by the National Research Oncology Center (NROC) in Kazakhstan. It outlines the journal's mission to serve as a pivotal interdisciplinary platform integrating these three rapidly evolving and interconnected fields. The editorial emphasizes the journal's commitment to addressing significant healthcare challenges at the national level in Kazakhstan, stimulating regional collaboration across Central Asia, and contributing to the global scientific discourse. The goal is to foster the exchange of original research, clinical experiences, and innovative practices to ultimately improve patient care and advance medical science in these critical specialties.

Keywords: Oncology; Nuclear Medicine; Transplantology; Kazakhstan

A Welcome from the Editor-in-Chief

It is with immense pride and a profound sense of responsibility that I welcome you to the inaugural issue of the journal *"Oncology, Nuclear Medicine and Transplantology."* Launched under the auspices of the National Research Oncology Center (NROC), this journal represents a pivotal step in our collective mission to advance medical science and improve patient outcomes. Our primary goal is to create a dynamic, interdisciplinary forum where groundbreaking research translates into tangible clinical progress.

Addressing National Priorities in Kazakhstan

In Kazakhstan, the burden of cancer and organ failure represents a significant challenge to our healthcare system [2, 3]. The National Research Oncology Center stands as a beacon of progress, embodying our nation's commitment to combating these diseases through innovation. The deployment of cutting-edge technologies—such as proton therapy, advanced radionuclide treatments, and molecular genetic diagnostics—has positioned NROC as a

The establishment of this journal is a strategic response to the evolving landscape of modern medicine. The boundaries between oncology, nuclear medicine, and transplantology are increasingly blurring, giving rise to powerful, integrated approaches to complex diseases [1]. This publication is founded on the conviction that the synergy of these specialties is essential for tackling the healthcare challenges of our time.

national reference center [4, 5]. This journal will serve as a crucial platform to disseminate these advancements across Kazakhstan, fostering a unified standard of excellence and supporting the continuous professional development of our medical community. It is a testament to our national resolve to not only adopt global standards but to contribute meaningfully to them

A Catalyst for Regional Advancement in Central Asia

The challenges we face in Kazakhstan are shared across Central Asia. Issues of access to advanced diagnostics, specialized surgical care, and novel therapeutics are common [6]. There is a pressing need for a regional platform that facilitates the exchange of knowledge, clinical experiences, and research findings specific to our demographic and epidemiological context. *"Oncology, Nuclear Medicine and Transplantology"* aims to be that catalyst. By

highlighting regional research on cancer epidemiology, the practical application of nuclear medicine in resource-conscious settings, and the development of sustainable transplant programs—including vital areas like bone marrow, liver, and kidney transplantation [7]—we hope to accelerate progress and build collaborative networks across Central Asia. Strengthening regional expertise is key to improving healthcare outcomes for millions.

Engaging with Global Scientific Discourse

On a global scale, medicine is navigating an era of unprecedented change. The rise in cancer incidence, the promise of personalized therapy, the revolution in radiopharmaceuticals for both diagnostics and treatment (theranostics) [8, 9], and the remarkable innovations in transplant immunology are defining the future of patient care [10]. To make a meaningful impact, we must engage actively in the worldwide scientific conversation. This journal is our invitation to that dialogue. We are committed to publishing high-quality, original research, insightful reviews, and challenging clinical cases that meet international

standards. We especially encourage submissions that explore the intersection of our core fields—for instance, the role of PET/CT in staging for transplant eligibility, or the use of radionuclide therapy as a bridge to transplantation.

Our mission is to build a bridge between scientists and clinicians in the CIS region and the international community. We are open to researchers from all corners of the world and believe that the diversity of perspectives enriches scientific discovery. True innovation is born from partnership.

Acknowledgement and a Look Forward

On behalf of the Editorial Board, I extend my deepest gratitude to the authors, reviewers, and dedicated colleagues whose unwavering support and

expertise have brought this vision to life. Launching a new journal is an endeavor built on collective faith and effort.

We are confident that, through our shared commitment, *“Oncology, Nuclear Medicine and Transplantology”* will grow into a respected and

influential publication—a platform where new ideas are ignited, and new horizons in patient care are forged. We invite you to read, submit, critique, and collaborate.

References

1. Zaidi H, Ojha N, editors. Molecular Imaging and Precision Medicine: A Multidisciplinary Approach. Springer International Publishing; 2019. DOI: [10.1007/978-3-030-17715-0](https://doi.org/10.1007/978-3-030-17715-0)
2. World Health Organization. Kazakhstan: Cancer Country Profile 2020. WHO; 2020. DOI: [10.37765/whocancer.2020.14](https://doi.org/10.37765/whocancer.2020.14)
3. Aimyshev T, Zhakhina G, Yerdessov S, et al. Mortality trends in Kazakhstan: insights from a million of deaths from 2014 to 2022. BMC Public Health. 2025;25(1):2312. DOI: [10.1186/s12889-025-23346-3](https://doi.org/10.1186/s12889-025-23346-3)
4. Beyembetova A, Ablayeva A, Akhmedullin R, Abdukhakimova D, Biniyazova A, Gaipov A. National Electronic Oncology Registry in Kazakhstan: Patient's Journey. Epidemiology and Health Data Insights. 2025;1(1):ehdi004. DOI: [10.63946/ehdi/16385](https://doi.org/10.63946/ehdi/16385)
5. Akhmedullin R, Aimyshev T, Zhakhina G, et al. In-depth analysis and trends of cancer mortality in Kazakhstan: a joinpoint analysis of nationwide healthcare data 2014-2022. BMC Cancer. 2024;24(1):1340. DOI: [10.1186/s12885-024-13128-2](https://doi.org/10.1186/s12885-024-13128-2)
6. Kaylangan L, et al. Health System Challenges and Opportunities in Central Asia: A Scoping Review. Lancet Reg Health Eur. 2021;5:100085. DOI: [10.1016/j.lanepe.2021.100085](https://doi.org/10.1016/j.lanepe.2021.100085)
7. Bikbov B, et al. Renal Replacement Therapy in Europe and Central Asia: An Analysis of Availability and Access. Kidney Int Rep. 2020;5(9):1423-32. DOI: [10.1016/j.ekir.2020.06.017](https://doi.org/10.1016/j.ekir.2020.06.017)
8. GBD 2019 Cancer Risk Factors Collaborators. The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022;400(10352):563-91. DOI: [10.1016/S0140-6736\(22\)01438-6](https://doi.org/10.1016/S0140-6736(22)01438-6)
9. Hennrich U, Kopka K. Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy. Pharmaceuticals. 2019;12(3):114. DOI: [10.3390/ph12030114](https://doi.org/10.3390/ph12030114)
10. Meier RPH, et al. Transplant Immunology and Precision Medicine: The Path to Personalized Immunosuppression. J Clin Med. 2022;11(17):5042. DOI: [10.3390/jcm11175042](https://doi.org/10.3390/jcm11175042)